Marrow fatty acids in osteoporosis: metabolic insights, emerging therapeutic targets.
Guo M., Miao Z., Xu R., Luo P., Li G.
Narrative Review, published in J Bone Miner Metab (2026) — summary generated from the PubMed abstract.
Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.
- Level A · Stronger Clinical Evidence
- Level B · Emerging clinical evidence with positive signals
- Level C · Early human research exploring benefits
- Level D · Scientific groundwork from lab and animal studies
- Emerging · Emerging topic under active research
This page is generated from the PubMed record. The Thai description is an automated summary of bibliographic fields and the abstract, not a full translation, and is not medical advice.
- Study type
- Narrative Review
- Journal
- J Bone Miner Metab (2026)
- Country
- Japan
- Reported sample size
- —
- Source database
- PubMed
- PMID
- 42295423
- DOI
- 10.1007/s00774-026-01737-9
Abstract (original English)
This review examines the role of marrow adipose tissue fatty acid composition in skeletal homeostasis, focusing on osteoporosis. To avoid conceptual confusion, we define evidence tiers: human studies assessing endogenous marrow lipid profiles; mechanistic studies applying exogenous fatty acids in vitro and in vivo; indirect MRI-based surrogates of marrow fat quantity; and direct ex vivo measurements of fatty acid composition via GC-MS, LC-MS, and lipidomics. We also clarify the distinction between marrow fat quantity and fatty acid quality. Human data reveal disease-, age-, and site-related alterations in marrow lipid saturation and unsaturation; however, findings vary by skeletal site, marrow compartment, fracture status, analytical platform, and study population. Experimental evidence demonstrates that saturated fatty acids (e.g., palmitic acid) induce lipotoxicity and osteoblast dysfunction, whereas unsaturated fatty acids (e.g., oleic acid and n-3 polyunsaturated fatty acids) exert protective effects via modulation of mesenchymal stem cell differentiation, osteoclastogenesis, ferroptosis, autophagy, and mitochondrial metabolism. Collectively, current evidence supports an association between marrow fatty acid biology and osteoporotic bone loss. Causal, diagnostic, and therapeutic implications remain preliminary. This review's main contribution is a fatty-acid-centered framew
What this study does not prove
- • This study does not prove SVF is an approved treatment or a replacement for standard care.
- • This is a narrative review: it collects no new patient data and does not systematically appraise evidence quality.
Evidence level
Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.
How we grade evidenceBrowse all related research
Filter the research library by this study's title keywords, author, or publication year.